[Federal Register Volume 78, Number 182 (Thursday, September 19, 2013)]
[Notices]
[Pages 57623-57624]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2013-22833]
-----------------------------------------------------------------------
DEPARTMENT OF DEFENSE
Office of the Secretary
TRICARE Over-the-Counter Drug Demonstration Project
AGENCY: Office of the Secretary, DoD.
ACTION: Notice of modification to the TRICARE Over-the-Counter Drug
Demonstration Project.
-----------------------------------------------------------------------
SUMMARY: This notice is to advise interested parties of a modification
of the demonstration project in which the Department of Defense (DoD)
evaluates allowing selected over-the-counter (OTC) drugs to be included
on the TRICARE uniform formulary. The Department has been engaged in a
demonstration project relating to Over the Counter (OTC) drugs since
2009. This demonstration project has been evaluating the costs/benefits
and beneficiary satisfaction of providing selected OTC drugs under the
pharmacy benefits program when the selected OTC drugs are determined to
be clinically effective and when recommended by the Pharmacy and
Therapeutics Committed and approved by the Assistant Secretary of
Defense (Health Affairs). Under the current demonstration, the eligible
[[Page 57624]]
drugs have been limited to those drugs for which the beneficiary has a
prescription for a drug in the same class and for which a clinically
effective OTC drug is also available. The current demonstration is
scheduled to end in November 2014. In the National Defense
Authorization Act for Fiscal Year 2013, Congress authorized the
Department to provide Over the Counter (OTC) drugs to beneficiaries
under regulations prescribed by the Secretary. Although the Department
could now cease the demonstration and implement this new Congressional
authority, it is now considering the viability of adding some drugs,
such as the Plan B One-Step (levonorgestrel) which is an OTC product
for all women of child-bearing potential that does not require a
prescription. It was decided that the most efficient method of testing
this new criteria was by modification to the current demonstration.
DATES: This demonstration project will continue through until November
30, 2016 in order to provide adequate time to implement and evaluate
the substantive changes allowing the DoD to provide drugs, such as the
Plan B One-Step, that are in the class of drugs normally requiring a
prescription but which the FDA has granted an exception to the
prescription requirement.
FOR FURTHER INFORMATION CONTACT: Captain Nita Sood, TRICARE Management
Activity, Pharmaceutical Operations Directorate, telephone (703) 681-
2890.
SUPPLEMENTARY INFORMATION:
Background
Section 705 of the John Warner National Defense Authorization Act
for 2007 directed the Secretary to conduct a demonstration project
under 10 United States Code (U.S.C.) 1092 to allow certain over-the-
counter (OTC) medications to be included on the uniform formulary under
10 U.S.C. 1074g. On June 15, 2007, the Department of Defense published
a notice in the Federal Register (FR) (72 FR 33208-33210) implementing
the demonstration project until the implementation of the combined
TRICARE mail and retail contract (TPharm) which was on November 4,
2009. In order to more thoroughly evaluate the clinical and cost
effectiveness of OTC drugs as well as beneficiary satisfaction with the
project, the Department published a notice in the FR (74 FR 66626-
66627) on December 16, 2009 that extended the demonstration project
through November 4, 2012. The Department determined that continuation
of the demonstration project for an additional 2 years was necessary to
provide the Secretary with sufficient information to fully evaluate the
project. The demonstration project continues to be authorized by 10
U.S.C. 1092. Section 702 of the National Defense Authorization Act for
Fiscal Year 2013 authorized the Department to provide OTC
pharmaceuticals under terms prescribed by the Secretary. This
authorization would allow the Department to implement its current
demonstration under its current terms. These terms have been to
authorize the provision of OTC drugs when the beneficiary had been
receiving prescription drugs in the same class and a clinically
effective OTC was available. These drugs were treated as generic
prescription medications, except that the need for a prescription and/
or a copay were waived. The OTC drugs must have been recommended by the
DoD Pharmacy and Therapeutics Committee and approved by the Assistant
Secretary of Defense, (Health Affairs) prior to inclusion on the
formulary. On June 20, 2013, the Food and Drug Administration (FDA)
announced the use of Plan B One-Step (levonorgestrel) emergency
contraceptive as an over-the-counter product ``for all women of child-
bearing potential without age or point-of-sale restrictions.''
Contraceptive drugs are a type of drug which normally would require a
prescription prior to dispensing, however the FDA made an exception for
this particular drug. The statute governing the Department's pharmacy
program, 10 U.S.C. 1074g, requires the Department to make available to
its beneficiaries all prescription drugs approved by the FDA. The
current issue for the Department regarding this drug, and any drugs for
which the FDA might issue similar exceptions and mandates, is to
determine how best to implement this requirement in our regulations.
The modifications to the current demonstration are designed to help the
Department determine whether these drugs can be treated in the same
manner as the other OTC drugs which moved from prescription to non-
prescription status.
Modification of the Demonstration Project
(1) Inclusion of the Over-the-Counter Plan B One-Step Emergency
Contraceptive (levonorgestrel).
(2) OTC availability of Plan B One-Step Emergency Contraceptive
(levonorgestrel) through the demonstration project will be at retail
dispensing venue. Eligibility includes all active duty service women
and female beneficiaries of child-bearing potential, without age
restrictions. All military treatment facility (MTF) pharmacies carry
OTC Plan B One-Step, and provide it to all active duty service women
and female beneficiaries of child-bearing potential, without age
restrictions, at no cost. The OTC Plan B One-Step Emergency
Contraceptive (levonorgestrel) will not be available through the
demonstration project at the TRICARE mail order program because it
would be clinically inappropriate to take OTC Plan B One-Step Emergency
Contraceptive (levonorgestrel) after 72 hours (3 days).
(3) Eligible beneficiaries will not require a written prescription
for Plan B One-Step Emergency Contraceptive (levonorgestrel). The
beneficiary simply presents to the retail pharmacy and which will
process the request identically to all other pharmacy claims.
(4) Cost sharing requirements. The cost sharing will be zero copay.
(5) Period of demonstration. The demonstration project will
continue until November 30, 2016.
Dated: September 16, 2013.
Aaron Siegel,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2013-22833 Filed 9-18-13; 8:45 am]
BILLING CODE 5001-06-P